23:27 , Mar 21, 2019 |  BC Extra  |  Clinical News

Conatus sinks after NASH therapy misses fibrosis endpoint

Conatus lost $1.49 (51%) to $1.42 in after-hours trading Thursday after reporting that emricasan missed the primary endpoint in the Phase IIb ENCORE-NF to treat non-alcoholic steatohepatitis fibrosis. ENCORE-NF's primary endpoint evaluated the proportion of...
21:54 , Dec 6, 2018 |  BC Week In Review  |  Clinical News

Conatus' emricasan misses in Phase IIb for NASH cirrhosis

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from baseline to week 24 vs. placebo in the Phase IIb ENCORE-PH trial...
20:01 , Dec 6, 2018 |  BC Extra  |  Clinical News

Conatus down on Phase IIb NASH miss

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) lost $2.56 (57%) to $1.94 on Thursday after it said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from baseline to week...
23:32 , Sep 14, 2018 |  BC Extra  |  Preclinical News

UCSD researchers identify mechanism, target in NASH

Researchers from the University of California San Diego have identified a key mechanism behind the pathogenesis of non-alcoholic steatohepatitis (NASH), which could lead to a therapeutic approach and biomarkers of disease progression. Caspases are suspected...
14:51 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Conatus' emricasan misses in Phase IIb in liver transplant patients

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said emricasan missed the primary endpoint of improving fibrosis in the Phase IIb POLT-HCV-SVR trial in post-orthotopic liver transplant recipients with fibrosis or cirrhosis. The trial enrolled 51 patients whose transplanted...
22:10 , Apr 5, 2018 |  BC Extra  |  Clinical News

Conatus falls as emricasan misses in liver transplant patients

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) fell $1.89 (31%) to $4.12 on Thursday after reporting that emricasan missed the primary endpoint of improving fibrosis in the Phase IIb POLT-HCV-SVR trial in post-orthotopic liver transplant recipients with fibrosis...
20:02 , Aug 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Necroptosis strikes again

Adding to the list of necroptosis-related pathologies, a group from Arizona State University has shown the cell death pathway is activated in Alzheimer’s disease. The data, published last month in Nature Neuroscience , identify potential...
20:34 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN

Debiopharm Group (Lausanne, Switzerland) completed enrollment of 96 patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN) in the Phase II portion of a double-blind, placebo-controlled, French and Swiss...
01:37 , May 5, 2017 |  BC Week In Review  |  Company News

Novartis exercises option for Conatus NASH candidate emricasan

Novartis AG (NYSE:NVS; SIX:NOVN) exercised an option for exclusive, worldwide rights to emricasan from Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) under a December 2016 deal. Conatus will receive a $7 million option exercise payment (see BioCentury, Dec....
01:21 , Jan 27, 2017 |  BC Innovations  |  Targets & Mechanisms

Death metal

The findings in two high profile papers on ferroptosis could be the nudge the fledgling field needs to gain the attention of drug developers. The process is the latest cell death pathway to offer up...